Andrea Maliachi
@AndreaMaliachi
Followers
632
Following
4K
Statuses
1K
MD Breast Medical Oncologist @incanMX & @UNAM_MX 🦀🐾 | (E)Spanglish
Mexiko
Joined June 2017
RT @DrYukselUrun: 🚨 Testicular Cancer Survivors: Long-term Risks Matter! 🔘23% of TCS experience worsening health post-cisplatin chemo. 🔘N…
0
17
0
RT @ESMO_Open: New on @ESMO_Open: A group of 36 pathologists re-evaluated 50 HER2 IHC slides that had been previously diagnosed as HER2 0.…
0
20
0
@OscarTahuahua … qué desalentador, eso explica el burnout. Tomar en cuenta que es una encuesta, hay que trabajar por mejorar el acceso a datos 📊
1
0
1
RT @OscarTahuahua: Cáncer Testicular 1/5 Alta Curabilidad ➡️ Diagnóstico-tratamiento oportuno es fundamental! Aquí algunos datos clave ⬇️…
0
118
0
RT @ABCGlobalAll: 📚 Study Alert: New research by @FatimaCardoso shows 87% of advanced breast cancer patients had jobs at diagnosis, but onl…
0
5
0
RT @guildsman: This 100%. I am not aware of a single predictive study demonstrating survival benefit with ctDNA to date. Also, despite BESP…
0
17
0
RT @DrRodrigoLastra: Brutales las desigualdades mundiales en el acceso a fármacos contra el cáncer. El 40% de la población no tiene acceso…
0
38
0
RT @incanMX: 🔔Convocatoria al 1er Premio "Dr. Jaime G. De la Garza Salazar" Dirigida a médicos (as) residentes del último año de los Cursos…
0
10
0
RT @javiercboj: That is an excellent point and some food for thought: if pCR is not a good surrogate for survival in GE cancers, what endpo…
0
2
0
RT @OncoAlert: A meta-analysis of the utility of cryotherapy for preventing peripheral neuropathy among #BreastCancer patients receiving pa…
0
17
0
Public Health in Mexico ⬇️ “Rather than functioning as an effective public health model, the system has become a platform for political careers.”
El el octogésimo segundo aniversario de @Tu_IMSS y respecto a mi tuit anterior, les dejo este análisis que escribí hace unas semanas sobre el daño que el paradigma reinante ha causado en la salud de los Mexicanos.
0
0
2
RT @to_be_elizabeth: 📌 Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges
0
15
0
RT @R_Graph_Gallery: 🚨 Stop chasing the p-value! Increasing your sample size will always yield a significant result. Even for trivial dif…
0
332
0
RT @dr_yakupergun: Current controversies in the use of Oncotype DX in early breast cancer 💥Excellent review👇 #bcsm
0
35
0
I have always believed the cdk4/6 inh feud was always about trial design… and the p-value used as an excellent sales tool (thnks Novartis).
There is no significant OS difference in first line Cdk inhibitors plus AI , amongst Palbociclib, Ribociclib and abemaciclib in MBC . Real world evidence in @ESMO_Open by @hoperugo @curijoey @stolaney1 Drug is as good or as bad as trial design ? Are all cdk inhibitors equal ? @oncology_bg
0
0
5
RT @SuyogCancer: There is no significant OS difference in first line Cdk inhibitors plus AI , amongst Palbociclib, Ribociclib and abemaci…
0
50
0
RT @OscarTahuahua: Risk factor of severe diarrhea and enterocolitis induced by CAPOX: a retrospective multicenter study (n=362) 1️⃣ Stati…
0
3
0